U.S. Markets close in 3 hrs 13 mins

How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug

ALLISON GATLIN
How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug

A collaboration with Swiss pharma giant Novartis could validate an experimental cancer treatment from biotech company Mirati Therapeutics, an analyst said Wednesday as Mirati stock rose.